CTXR Stock Overview
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Citius Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.77 |
| 52 Week High | US$1.56 |
| 52 Week Low | US$0.60 |
| Beta | 1.51 |
| 1 Month Change | -4.33% |
| 3 Month Change | 17.49% |
| 1 Year Change | -44.80% |
| 3 Year Change | -61.05% |
| 5 Year Change | -23.27% |
| Change since IPO | -94.88% |
Recent News & Updates
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18Shareholder Returns
| CTXR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.0% | 0.9% | 1.2% |
| 1Y | -44.8% | 13.9% | 24.7% |
Return vs Industry: CTXR underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: CTXR underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| CTXR volatility | |
|---|---|
| CTXR Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CTXR's share price has been volatile over the past 3 months.
Volatility Over Time: CTXR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 22 | Leonard Mazur | citiuspharma.com |
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc. Fundamentals Summary
| CTXR fundamental statistics | |
|---|---|
| Market cap | US$122.07m |
| Earnings (TTM) | -US$39.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs CTXR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTXR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$39.33m |
| Earnings | -US$39.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CTXR perform over the long term?
See historical performance and comparison